mcmmaf

McMMAF is a protective group-conjugated MMAF. MMAF is a potent tubulin polymerization inhibitor.It is a MMAF derivative having a Maleimidocaproyl linker (MC linker), which is ready to conjugate to antibody or other proteins or biopolymers. Mafodotin is a useful agent for make antibody drug conjugate (ADC) for targeted drug delivery.

Vorsetuzumab mafodotin, a humanized anti-CD70 monoclonal antibody, conjugates with monomethyl auristatin F (MMAF) through Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. This affinity allows targeting of various solid tumors and cancers such as renal cell carcinoma, pancreatic, ovarian, and lung cancers, alongside multiple myeloma and several forms of non-Hodgkin lymphoma, all of which express CD70.

Cys-McMMAF, the active compound liberated from AlMcMMAF—a humanized anti-5T4 A1 antibody connected to the microtubule-disrupting molecule MMAF through a maleimidocaproyl linker—demonstrates antitumor effectiveness in two mouse tumor models (H1975 and MDA-MB-361-DYT2) [1].

Anti-SLC34A2 (Lifastuzumab)-McMMAF is an antibody-drug conjugate (ADC) composed of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab, linked to the protective group maleimidocaproyl, and the tubulin inhibitor MMAF. The toxic component and linker in this ADC are McMMAF. Anti-SLC34A2 (Lifastuzumab)-McMMAF can induce apoptosis and is utilized in cancer research.

Anti-CCL2 (Carlumab)-McMMAF is an antibody-drug conjugate (ADC) composed of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab, linked with the protective group maleimidocaproyl and the tubulin inhibitor MMAF. The cytotoxic molecule and linker in this ADC are McMMAF. Anti-CCL2 (Carlumab)-McMMAF can induce apoptosis and is used in cancer research.

ADC Control Human IgG1-McMMAF is an antibody-drug conjugate (ADC) comprising the ADC antibody IgG1 Human IgG1 kappa, Isotype Control, and the payload McMMAF.

Denintuzumab-MMAF, an ADC, combines a CD19-directed antibody with McMMAF and is utilized in researching acute lymphoblastic leukemia.

Depatuxizumab-MMAF, an antibody-drug conjugate (ADC), comprises an EGFR-targeted antibody linked to McMMAF and is utilized in glioblastoma research.